Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 8
Submit an article Journal homepage
817
Views
42
CrossRef citations to date
0
Altmetric
Original Articles: Research

Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells

Grace I. Aldana-Masangkay
,
Agustin Rodriguez-GonzalezUniversity of Heidelburg, Germany
,
Tara LinDivision of Hematology/Oncology, Department of Medicine, Louisiana State University, New Orleans, LA, USA
,
Alan K. IkedaDivision of Hematology/Oncology, Department of Pediatrics, Gwynne Hazen Cherry Memorial Laboratories, Mattel Children's Hospital UCLA, Jonsson Comprehensive Cancer Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Molecular Biology Institute, California Nanosystems Institute, UCLA, Los Angeles, CA, USA
,
Yao-Te HsiehDivision of Hematology/Oncology, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
,
Yong-Mi KimDivision of Hematology/Oncology, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
,
Brett LomenickDepartment of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, USA
,
Kazuo OkemotoDepartment of Neurological Surgery, Ohio State University, OH, USA
,
Elliot M. LandawDepartment of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
,
Dongpeng WangCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
,
Ralph MazitschekCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
,
James E. BradnerDana-Farber Cancer Institute, Boston, MA, USA
&
Kathleen M. SakamotoDivision of Hematology/Oncology, Department of Pediatrics, Gwynne Hazen Cherry Memorial Laboratories, Mattel Children's Hospital UCLA, Jonsson Comprehensive Cancer Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Molecular Biology Institute, California Nanosystems Institute, UCLA, Los Angeles, CA, USACorrespondence[email protected]
 show all
Pages 1544-1555 | Received 08 Feb 2011, Accepted 27 Feb 2011, Published online: 23 Jun 2011

Citations (42)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Shaymaa E. Kassab, Samar Mowafy, Aya M. Alserw, Joustin A. Seliem, Shahenda M. El-Naggar, Nesreen N. Omar & Mohamed M. Awad. (2019) Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma. Journal of Enzyme Inhibition and Medicinal Chemistry 34:1, pages 1062-1077.
Read now
Na Shao, Jie Zou, Jie Li, Feng Chen, Jianjian Dai, Xun Qu, Xiulian Sun, Daoxin Ma & Chunyan Ji. (2012) Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia. Leukemia & Lymphoma 53:9, pages 1769-1778.
Read now
Elizabeth A. Eklund & Leonidas C. Platanias. (2011) Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia. Leukemia & Lymphoma 52:8, pages 1421-1422.
Read now

Articles from other publishers (39)

C. Mardones, C. Navarrete-Munoz, ME Armijo, K. Salgado, F. Rivas-Valdes, V. Gonzalez-Pecchi, C. Farkas, A. Villagra & MI Hepp. (2023) Role of HDAC6-STAT3 in immunomodulatory pathways in Colorectal cancer cells. Molecular Immunology 164, pages 98-111.
Crossref
Miao Yan, Heng Cao, Kangjia Tao, Bing Xiao, Yifan Chu, Ding Ma, Xiaoyuan Huang, Yingyan Han & Teng Ji. (2023) HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers. Gene 885, pages 147704.
Crossref
Yun Deng, Qian Cheng & Jing He. (2023) HDAC inhibitors: Promising agents for leukemia treatment. Biochemical and Biophysical Research Communications 680, pages 61-72.
Crossref
A. N. Kukushkin, S. B. Svetlikova, N. D. Aksenov & V. A. Pospelov. (2023) Tubacin Histone Deacetylase 6 Inhibitor Produced α-Tubulin Acetylation, Cell Cycle Arrest, Aging, and Suppression of Migration of Mouse Fibroblasts Transformed by E1A and cHa-ras Oncogenes. Cell and Tissue Biology 17:2, pages 133-145.
Crossref
灿章 吴. (2023) Tubacin plus Erastin Treatment Sensitizes Cell Ferroptosis of Triple Negative Breast Neoplasms. Advances in Clinical Medicine 13:05, pages 8741-8748.
Crossref
灿章 吴. (2023) Erastin plus Tubacin Treatment Promotes Breast Cancer Cell Death of HCC38. Advances in Clinical Medicine 13:05, pages 8733-8740.
Crossref
Kaneez Fatima, Nusrat Masood, Zahoor Ahmad Wani, Abha Meena & Suaib Luqman. (2021) Neomenthol prevents the proliferation of skin cancer cells by restraining tubulin polymerization and hyaluronidase activity. Journal of Advanced Research 34, pages 93-107.
Crossref
Shouying Xu & Chao Tang. (2021) The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?. Frontiers in Oncology 11.
Crossref
Rui Chen, Mengxian Zhang, Yangmei Zhou, Wenjing Guo, Ming Yi, Ziyan Zhang, Yanpeng Ding & Yali Wang. (2020) The application of histone deacetylases inhibitors in glioblastoma. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Jia Yang, Dengwen Li & Jun Zhou. (2020) Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies. Frontiers in Pharmacology 11.
Crossref
Loredana Cappellacci, Diego R. Perinelli, Filippo Maggi, Mario Grifantini & Riccardo Petrelli. (2020) Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Current Medicinal Chemistry 27:15, pages 2449-2493.
Crossref
Hélène Losson, Michael Schnekenburger, Mario Dicato & Marc Diederich. (2020) HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?. Cancers 12:2, pages 318.
Crossref
Ann Lin, Christopher J. Giuliano, Ann PalladinoKristen M. John, Connor AbramowiczMonet Lou YuanErin L. SausvilleDevon A. LukowLuwei LiuAlexander R. Chait, Zachary C. Galluzzo, Clara Tucker & Jason M. Sheltzer. (2019) Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Science Translational Medicine 11:509.
Crossref
Hye‑Rim Won, Dong Hoon Lee, Soo‑Keun Yeon, Hyun‑Wook Ryu, Go Woon Kim & So Hee Kwon. (2019) HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma. International Journal of Oncology.
Crossref
Dong Hoon Lee, Go Woon Kim & So Hee Kwon. (2019) The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Molecular Carcinogenesis 58:6, pages 944-956.
Crossref
Baojie Zhang, Bin Liu, Deng Chen, Rita Setroikromo, Hidde J. Haisma & Wim J. Quax. (2019) Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. Cancers 11:5, pages 645.
Crossref
Karin Sadoul, Clotilde Joubert, Sophie Michallet, Elsie Nolte, Lauralie Peronne, Sacnicté Ramirez-Rios, Anne-Sophie Ribba & Laurence Lafanechère. (2019) Déchiffrage du code tubuline. médecine/sciences 34:12, pages 1047-1055.
Crossref
Manon Lernoux, Michael Schnekenburger, Mario Dicato & Marc Diederich. (2018) Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacological Research 129, pages 337-356.
Crossref
Yixuan Li & Edward Seto. (2016) HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harbor Perspectives in Medicine 6:10, pages a026831.
Crossref
Sara Ota, Zi-Qiang Zhou, Megan P. Romero, Guang Yang & Peter J. Hurlin. (2016) HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia. Human Molecular Genetics 25:19, pages 4227-4243.
Crossref
Jeanne Froehlich, Margaux Versapuech, Laura Megrelis, Quitterie Largeteau, Sylvain Meunier, Corinne Tanchot, Georges Bismuth, Jérôme Delon & Marianne Mangeney. (2016) FAM65B controls the proliferation of transformed and primary T cells. Oncotarget 7:39, pages 63215-63225.
Crossref
Gregory W Watson, Samanthi Wickramasekara, Yufeng Fang, Claudia S Maier, David E Williams, Roderick H Dashwood, Viviana I Perez & Emily Ho. (2015) HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells. Experimental Biology and Medicine 241:11, pages 1177-1185.
Crossref
M Pinazza, C Borga, V Agnusdei, S Minuzzo, G Fossati, M Paganin, B Michielotto, A De Paoli, G Basso, A Amadori, G te Kronnie & S Indraccolo. (2016) An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death & Disease 7:1, pages e2047-e2047.
Crossref
Jui-Ling Hsu, Fan-Lun Liu, Lih-Ching Hsu, Hsun-Shuo Chang, Wohn-Jenn Leu, Chia-Chun Yu, Wei-Ling Chang, Ih-Sheng Chen, Fan-Lu Kung & Jih-Hwa Guh. (2015) Epi -reevesioside F inhibits Na+/K+-ATPase, causing cytosolic acidification, Bak activation and apoptosis in glioblastoma . Oncotarget 6:27, pages 24032-24046.
Crossref
Leila Haery, Ryan C. Thompson & Thomas D. Gilmore. (2015) Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes & Cancer 6:5-6, pages 184-213.
Crossref
Pavan Kumar Dhanyamraju, Philipp Simon Holz, Florian Finkernagel, Volker Fendrich & Matthias Lauth. (2015) Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway. Molecular Cancer Therapeutics 14:3, pages 727-739.
Crossref
Ansgar Brüning & Julia Jückstock. (2015) Misfolded Proteins: From Little Villains to Little Helpers in the Fight Against Cancer. Frontiers in Oncology 5.
Crossref
Pierfausto Seneci. 2015. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease 135 172 .
Anna Pastò, Chiara Bellio, Giorgia Pilotto, Vincenzo Ciminale, Micol Silic-Benussi, Giulia Guzzo, Andrea Rasola, Chiara Frasson, Giorgia Nardo, Elisabetta Zulato, Maria Ornella Nicoletto, Mariangela Manicone, Stefano Indraccolo & Alberto Amadori. (2014) Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget 5:12, pages 4305-4319.
Crossref
D Koyama, J Kikuchi, N Hiraoka, T Wada, H Kurosawa, S Chiba & Y Furukawa. (2013) Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 28:6, pages 1216-1226.
Crossref
Wohn-Jenn Leu, Hsun-Shuo Chang, She-Hung Chan, Jui-Ling Hsu, Chia-Chun Yu, Lih-Ching Hsu, Ih-Sheng Chen & Jih-Hwa Guh. (2014) Reevesioside A, a Cardenolide Glycoside, Induces Anticancer Activity against Human Hormone-Refractory Prostate Cancers through Suppression of c-myc Expression and Induction of G1 Arrest of the Cell Cycle. PLoS ONE 9:1, pages e87323.
Crossref
Ying Cai, Wenli Cui, Weixiang Chen, Ping Wei, Yayun Chi, Ping Zhang, Rui Bi & Xiaoyan Zhou. (2013) The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell International 13:1.
Crossref
Jay H. Kalin & Joel A. Bergman. (2013) Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors. Journal of Medicinal Chemistry 56:16, pages 6297-6313.
Crossref
Mihnea T. Zdrenghea. (2013) Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?. Medical Hypotheses 81:2, pages 311-315.
Crossref
Seiichiro Komatsu, Shota Moriya, Xiao-Fang Che, Tomohisa Yokoyama, Norio Kohno & Keisuke Miyazawa. (2013) Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochemical and Biophysical Research Communications 437:1, pages 41-47.
Crossref
Jinhua TangHaidong Yan & Shougang Zhuang. (2013) Histone deacetylases as targets for treatment of multiple diseases. Clinical Science 124:11, pages 651-662.
Crossref
Bruna Barneda-Zahonero & Maribel Parra. (2012) Histone deacetylases and cancer. Molecular Oncology 6:6, pages 579-589.
Crossref
Sophia N Ononye, Michael van Heyst, Eric M Falcone, Amy C Anderson & Dennis L Wright. (2012) Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharmaceutical Patent Analyst 1:2, pages 207-221.
Crossref
Elizabeth S. Inks, Benjamin J. Josey, Sean R. Jesinkey & C. James Chou. (2011) A Novel Class of Small Molecule Inhibitors of HDAC6. ACS Chemical Biology 7:2, pages 331-339.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.